>>Signaling Pathways>> PI3K/Akt/mTOR Signaling>> mTOR>>RP-3500

RP-3500 (Synonyms: RP-3500; ATR inhibitor 4)

Catalog No.GC64278

RP-3500(ATR 억제제 4)은 생화학적 분석에서 IC50이 1.00nM인 경구 활성 선택적 ATR 키나제 억제제(ATRi)입니다. RP-3500은 mTOR(IC50=120nM)에 비해 ATR에 대해 30배 선택성 및 ATM, DNA-PK 및 PI3Kα 키나제에 대해 >2,000배 선택성을 보여줍니다. RP-3500은 강력한 항종양 활성을 가지고 있습니다.

Products are for research use only. Not for human use. We do not sell to patients.

RP-3500 Chemical Structure

Cas No.: 2417489-10-0

Size 가격 재고 수량
5 mg
US$580.00
재고 있음
10 mg
US$918.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com

고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

RP-3500 (ATR inhibitor 4) is an orally active, selective ATR kinase inhibitor (ATRi) with an IC50 of 1.00 nM in biochemical assays. RP-3500 shows 30-fold selectivity for ATR over mTOR (IC50=120 nM) and >2,000-fold selectivity over ATM, DNA-PK, and PI3Kα kinases. RP-3500 has potent antitumor activity[1].

RP-3500 (ATR inhibitor 4; 1 μM; 1-24 hours) inhibits CHK1(Ser345) phosphorylation from 1 to 3 hours[1]. RP-3500 inhibits Gemcitabine stimulated ATR phosphorylation of its substrate pCHK1(Ser345) with an IC50 of 0.33 nM in a LoVo cell-based assay[1].

RP-3500 (ATR inhibitor 4; 3, 7, 15 mg/kg; Orally; once daily for 18 days) produces dose-dependent tumor growth inhibition with a minimum effective dose (MED) of 7 mg/kg in LoVo xenografts[1]. RP-3500 (5, 10 mg/kg; Orally; once daily) produces statistically significant tumor growth inhibition in the CW-2 colon xenograft model[1]. RP-3500 (7 mg/kg; for 7 days) results in 8.1- and 2.7-fold inductions of KAP1 and DNA-PKcs phosphorylation in mice bearing LoVo tumors[1]. RP-3500 has a more profound anti-tumor effect occurred at higher doses on the 3 days on/4 days off (30 mg/kg) and 5 days on/2 days off (25 mg/kg) schedules compared with consecutive daily administrations (10 mg/kg) at a lower dose for 14 days[1]. RP-3500 (15mg/kg) combined PARPi Olaparib (80mg/kg; both agents days 1-3 on/4 days off) or sequential (PARPi for 3 days followed by RP-3500 for 3 days then 1 day off) schedules produces greater antiTumor effects compared with sequential administration without affecting tolerability[1].

[1]. Anne Roulston, et al. RP-3500: A Novel, Potent and Selective ATR Inhibitor that is Effective in Preclinical Models as a Monotherapy and in Combination with PARP Inhibitors. Mol Cancer Ther

리뷰

Review for RP-3500

Average Rating: 5 ★★★★★ (Based on Reviews and 24 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for RP-3500

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.